1. Generics Bulletin
  2. >>Business
  3. >>Strategy

US Pricing Pressure Spotlights Regulatory Compliance As Key To Indian Companies’ Performance

Countering Strategies In Play

 
• By Vibha Ravi

While generic drug prices continued to erode in the US during the second quarter of FY23, compliance will be key to the performance of Indian firms such as Torrent and Jubilant through the rest of the year. The US FDA has issued multiple observations in 2022, but an import alert for Glenmark’s Baddi unit is the harshest so far.

FDA Approved
FDA's Moves Will Have Greater Impact On Financial Performance • Source: Shutterstock

Indian companies saw continued erosion of generic drug prices in the US during the second quarter of fiscal year 2023, which ends 31 March, management commentary from companies which have announced earnings so far indicates.

While that has been so for a couple of quarters now, the impact is exacerbated by a spike in input and logistics costs. Compliance with good manufacturing practices and the US Food and Drug Administration’s pronouncements in this regard assume greater significance against this background

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business